AL Amyloidosis: Clinical Trials

14 trials for AL Amyloidosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 active not recruiting, 2 recruiting, 2 terminated. 14 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 114Completed 7, Active not recruiting 2, Recruiting 2, Terminated 2, Withdrawn 1
Phase 28Completed 4, Recruiting 2, Active not recruiting 1, Withdrawn 1

Follow AL Amyloidosis: new trials by email Literature Review of AL Amyloidosis trials Research Report on AL Amyloidosis

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Elranatamab - AL Amyloidosis
Phase 1 / Phase 2RecruitingDana-Farber Cancer Institute492024-11-012026-08-19
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 weeks) - AL Amyloidosis, Amyloidosis
Phase 1 / Phase 2RecruitingUniversity of Texas Southwestern Medical Center372024-02-152026-08-19
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
Venetoclax, Dexamethasone, Daratumumab - AL Amyloidosis, Light Chain (AL) Amyloidosis
Phase 1 / Phase 2WithdrawnAlfred Chung, MD2024-01-082025-03-06
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis
Phase 1 / Phase 2Active not recruitingColumbia University532022-10-262026-10-08
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
ZN-d5 - Amyloidosis, AL Amyloidosis
Phase 1 / Phase 2CompletedK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.182021-11-302024-09-19
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Bortezomib, Cyclophosphamide, Dexamethasone - AL Amyloidosis
Phase 1Active not recruitingEmory University112021-04-282026-07-14
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Melphalan-Flufenamide (Melflufen), Dexamethasone - AL Amyloidosis
Phase 1TerminatedOncopeptides AB62020-08-062022-03-28
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Ixazomib, Cyclophosphamide, Dexamethasone - AL Amyloidosis
Phase 1 / Phase 2CompletedIcahn School of Medicine at Mount Sinai282017-06-122022-09-29
Daratumumab for the Treatment of Patients With AL Amyloidosis
daratumumab - AL Amyloidosis
Phase 1 / Phase 2CompletedBoston Medical Center222017-03-202021-05-07
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Venetoclax, Dexamethasone - AL Amyloidosis
Phase 1TerminatedTufts Medical Center32017-01-012020-08-21
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4 - AL Amyloidosis
Phase 1CompletedAlexion Pharmaceuticals, Inc.302014-10-302025-02-07
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Pomalidomide, Dexamethasone - AL Amyloidosis
Phase 1 / Phase 2CompletedBoston Medical Center272012-06-012020-09-22
Radioimmunoimaging of Light Chain (AL) Amyloidosis
Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg) - AL Amyloidosis
Phase 1CompletedUniversity of Tennessee302008-12-012013-09-18
Radioimmunoimaging of AL Amyloidosis
124I-labeled monoclonal antibody Mu 11-1F4 - AL Amyloidosis
Phase 1CompletedUniversity of Tennessee382008-11-012012-10-11

Narrower conditions

Immunoglobulin Light-chain Amyloidosis (14)  ·  Amyloidosis (4)  ·  Alzheimer Disease (1)  ·  Proteostasis Deficiencies (1)  ·  Recurrence (1)

Broader conditions

Immune System Diseases (14)  ·  Immunoproliferative Disorders (14)  ·  Lymphoproliferative Disorders (14)  ·  Metabolic Diseases (14)  ·  Neoplasms (14)  ·  Neoplasms by Histologic Type (14)  ·  Neoplasms, Plasma Cell (14)  ·  Nutritional and Metabolic Diseases (14)  ·  Paraproteinemias (14)  ·  Proteostasis Deficiencies (13)  ·  Amyloidosis (10)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Dementia (1)  ·  Disease Attributes (1)

Interventions

Dexamethasone (7)  ·  Calcium Dobesilate (4)  ·  daratumumab (3)  ·  venetoclax (3)  ·  Cyclophosphamide (2)  ·  dexamethasone acetate (2)  ·  ixazomib (2)  ·  pomalidomide (2)  ·  Bendamustine Hydrochloride (1)  ·  Biological Assay (1)  ·  Bortezomib (1)  ·  Drug Evaluation (1)  ·  In Situ Hybridization (1)  ·  In Situ Hybridization, Fluorescence (1)  ·  auricularum (1)

Sponsors

Boston Medical Center (2)  ·  University of Tennessee (2)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Alfred Chung, MD (1)  ·  Columbia University (1)  ·  Dana-Farber Cancer Institute (1)  ·  Emory University (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (1)  ·  Oncopeptides AB (1)  ·  Tufts Medical Center (1)  ·  University of Texas Southwestern Medical Center (1)

Countries

United States (13)  ·  Greece (2)  ·  Israel (2)  ·  Spain (2)  ·  Australia (1)  ·  Cyprus (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Norway (1)  ·  United Kingdom (1)

Top investigators

Vaishali Sanchorawala, MD (2)  ·  Alfred Chung, MD (1)  ·  Andrew Eisenberger, MD (1)  ·  Craig C Hofmeister, MD, MPH (1)  ·  Giada Bianchi (1)  ·  Giovanni Palladini, MD (1)  ·  Keren Osman, MD (1)  ·  Larry Anderson, MD (1)  ·  Rajshekhar Chakraborty, MD (1)  ·  Raymond Comenzo, MD (1)

Results publications

PMID 40226119, PMID 27381904, PMID 31978210, PMID 34521113

NIH funding

P30CA138292 (1)